Status:
COMPLETED
Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The objective of the study is to investigate the relative bioavailability of the final tablet formulation (FF) of BI 10773 in comparison to the tablet formulation 2 (TF2).
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Healthy male and female subjects
Exclusion
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01242176
Start Date
November 1 2010
Last Update
June 18 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1245.51.1 Boehringer Ingelheim Investigational Site
Biberach, Germany